Alterations of immune response of non-small cell lung cancer with Azacytidine

Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting PD-L1/PD-1 interaction. NSCLC cell lines were...

Descripción completa

Detalles Bibliográficos
Autores principales: Wrangle, John, Wang, Wei, Koch, Alexander, Easwaran, Hariharan, Mohammad, Helai P., Vendetti, Frank, VanCriekinge, Wim, DeMeyer, Tim, Du, Zhengzong, Parsana, Princy, Rodgers, Kristen, Yen, Ray-Whay, Zahnow, Cynthia A., Taube, Janis M., Brahmer, Julie R., Tykodi, Scott S., Easton, Keith, Carvajal, Richard D., Jones, Peter A., Laird, Peter W., Weisenberger, Daniel J., Tsai, Salina, Juergens, Rosalyn A., Topalian, Suzanne L., Rudin, Charles M., Brock, Malcolm V., Pardoll, Drew, Baylin, Stephen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875770/
https://www.ncbi.nlm.nih.gov/pubmed/24162015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875770/
https://www.ncbi.nlm.nih.gov/pubmed/24162015

Ejemplares similares